seekingalpha.com
Photocure ASA (PHCUF) Q4 2025 Earnings Call Transcript
Photocure ASA (PHCUF) Q4 2025 Earnings Call Transcript
PHCUFPHCUFOTC
Loading
Latest News
Loading news...
prnewswire.com
Photocure ASA: Results for the fourth quarter of 2025
OSLO, Norway, Feb. 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a commercial EBITDA of NOK 8.4 million (Q4 2024: NOK 3.9 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and continued operating leverage flow-through in its core Hexvix ® /Cysview ® commercial business.
seekingalpha.com
Photocure ASA (PHCUF) Q3 2025 Earnings Call Transcript
Photocure ASA (OTCPK:PHCUF) Q3 2025 Earnings Call October 29, 2025 9:00 AM EDT Company Participants Daniel Schneider - President & CEO Erik Dahl - Chief Financial Officer Presentation Daniel Schneider President & CEO All right. Well, welcome to Photocure's Third Quarter 2025 Results.
prnewswire.com
Photocure ASA: Results for the third quarter of 2025
OSLO, Norway , Oct. 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 million) for the company. Looking ahead, Photocure expects product revenue growth in the range of 8% to 10% on a constant currency basis (compared to 7 to 11% previously) and an EBITDA improvement in 2025.
prnewswire.com
Photocure ASA: Results for the second quarter of 2025
OSLO, Norway , July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and an EBITDA of NOK 14.8 million (Q2 2024: NOK 27.8 million, including a milestone payment of NOK 21.6 million) for the company. Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025.
prnewswire.com
Photocure ASA: Results for the first quarter of 2025
OSLO, Norway , May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million), and an EBITDA of NOK 1.8 million (7.9) for the company. Photocure expects product revenue growth in the range of 7% to 11% and YoY EBITDA improvement in 2025.
prnewswire.com
Photocure ASA: Results for the fourth quarter of 2024
OSLO, Norway , Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK 29.9 million). Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025.
prnewswire.com
Photocure ASA: Results for the third quarter of 2024
OSLO, Norway , Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and EBITDA of NOK 5.0 million (NOK 3.3 million) for the Company. Photocure reiterates its 2024 financial guidance and continues to expect consolidated product revenue growth of 6% to 9% in constant currency and positive EBITDA excluding business development expenses.